Compare ATKR & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATKR | KOD |
|---|---|---|
| Founded | 1959 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2016 | 2018 |
| Metric | ATKR | KOD |
|---|---|---|
| Price | $93.87 | $35.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $75.67 | $35.43 |
| AVG Volume (30 Days) | ★ 685.0K | 533.8K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,850,378,000.00 | N/A |
| Revenue This Year | $6.55 | N/A |
| Revenue Next Year | $3.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $53.75 | $8.91 |
| 52 Week High | $94.14 | $47.84 |
| Indicator | ATKR | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 71.71 | 34.48 |
| Support Level | $93.32 | $32.93 |
| Resistance Level | $94.05 | $45.77 |
| Average True Range (ATR) | 0.22 | 1.95 |
| MACD | -0.65 | -0.47 |
| Stochastic Oscillator | 95.54 | 14.10 |
Atkore Inc is a manufacturer of Electrical products for the non-residential construction and renovation markets, as well as residential markets, and Safety & Infrastructure products for the construction and industrial markets. The Electrical segment manufactures products used in the construction of electrical power systems including conduit, cable, and installation accessories. This segment serves contractors in partnership with the electrical wholesale channel. The Safety & Infrastructure segment designs and manufactures solutions including metal framing, mechanical pipe, perimeter security, and cable management. These solutions are marketed to contractors, original equipment manufacturers (OEMs), and end-users. The majority of revenue is generated from the Electrical segment.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.